31 August 2025
Novo Nordisk: Wegovy® Reduces Heart Attack, Stroke, Death Risk by 57% vs. Tirzepatide
Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.
